目次

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY
2.2 RESEARCH OBJECTIVE
2.3 MARKET

3 RESEARCH METHODOLOGY
3.1 OVERVIEW
3.2 DATA FLOW
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
3.5.1 PRIMARY
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
3.6.1 REVENUE
3.7 DATA FORECASTING
3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
3.8.1 MICROECONOMIC FACTOR ANALYSIS:
3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS
4.1 INTRODUCTION
4.2 DRIVERS
4.2.1 HIGH PREVALENCE OF INFECTIOUS DISEASES IN WOMEN
4.2.2 GROWING STRATEGIC INITIATIVES
4.3 RESTRAINTS
4.3.1 INACCURACY OF POINT OF CARE DIAGNOSTIC TESTS
4.4 OPPORTUNITY
4.4.1 HIGH COST OF DIAGNOSTIC IMAGING

5 MARKET FACTOR ANALYSIS
5.1 PORTER'S FIVE FORCES
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 BARGAINING POWER OF SUPPLIERS
5.1.3 THREAT OF SUBSTITUTES
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY
5.2 IMPACT OF COVID-19 ON THE GLOBAL POINT-OF-CARE TESTING FOR WOMEN
5.3 CONSUMER PREFERENCE ANALYSIS
5.4 REGULATORY LANDSCAPE
5.4.1 REGULATORY
5.4.2 ENVIRONMENTAL CONSIDERATIONS FOR COLLOIDAL GOLD PRODUCTS

6 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT
6.1 OVERVIEW
6.2 INSTRUMENTS/DEVICES
6.3 REAGENTS & KITS
6.4 CONSUMABLES
6.5 OVERVIEW
6.6 ADOLESCENT
6.7 ADULT
6.8 GERIATRIC

7 GLOBAL POINT-OF-CARE TESTING
7.1 OVERVIEW
7.2 SERUM
7.3 WHOLE BLOOD
7.4 URINE
7.5 OTHERS

8 GLOBAL POINT-OF-CARE
8.1 OVERVIEW
8.2 TESTOSTERONE
8.3 ESTRADIOL TEST
8.4 ANTI-MÜLLERIAN HORMONE TEST
8.5 PROGESTERONE TEST
8.6 FOLLICLE-STIMULATING HORMONE
8.7 LUTEINIZING HORMONE TEST
8.8 Β-HCG TEST
8.9 OTHERS

9 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY
9.1 COLLOIDAL GOLD LATERAL FLOW ASSAYS
9.2 FLUORESCENCE IMMUNOASSAYS
9.3 LAB-ON-A-CHIP
9.4 OTHERS

10 GLOBAL POINT-OF-CARE TESTING FOR WOMEN
10.1 OVERVIEW
10.2 GESTATIONAL DIABETES
10.3 VAGINAL INFECTION
10.4 URINARY TRACT INFECTION
10.5 CERVICAL CANCER
10.6 HEMOGLOBIN DEFICIENCY
10.7 BREAST CANCER
10.8 THYROID DISEASE
10.9 SEXUALLY TRANSMITTED INFECTIONS
10.9.1 CHLAMYDIA
10.9.2 GONORRHEA
10.9.3 HIV
10.9.4 SYPHILIS
10.9.5 OTHERS
10.9.6 POLYCYSTIC OVARY SYNDROME
10.9.7 OVULATION
10.9.8 OTHERS
10.10 PREGNANCY TESTING
10.11 OTHERS

11 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 OFFLINE
11.2.1 HOSPITAL PHARMACIES
11.2.2 RETAIL
11.2.3 HYPERMARKET/SUPERMARKET
11.3 ONLINE
11.3.1 E-COMMERCE
11.3.2 ONLINE PHARMACIES

12 GLOBAL POINT-OF-CARE TESTING FOR
12.1 OVERVIEW
12.2 HOSPITALS
12.3 HOME SETTINGS
12.4 OTHERS

13 GLOBAL
13.1 OVERVIEW
13.1.1 US
13.1.2 CANADA
13.1.3 MEXICO
13.2 EUROPE
13.2.1 GERMANY
13.2.2 FRANCE
13.2.3 UK
13.2.4 ITALY
13.2.5 REST OF EUROPE
13.3 ASIA-PACIFIC
13.3.1 CHINA
13.3.2 JAPAN
13.3.3 AUSTRALIA
13.3.4 SOUTH KOREA
13.3.5 REST OF ASIA-PACIFIC
13.4 REST OF THE WORLD
13.4.1 MIDDLE EAST & AFRICA
13.4.2 SOUTH AMERICA

14 COMPETITIVE LANDSCAPE
14.1 INTRODUCTION
14.2 MARKET SHARE ANALYSIS,
14.3 COMPETITOR DASHBOARD
14.4 PUBLIC PLAYERS STOCK SUMMARY
14.5 KEY DEVELOPMENTS & GROWTH
14.5.1 PRODUCT LAUNCH
14.5.2 TECHNOLOGY LAUNCH
14.5.3 PRODUCT RECOGNITION

15 COMPANY PROFILES
15.1 SWISS
15.1.1 COMPANY OVERVIEW
15.1.2 FINANCIAL OVERVIEW
15.1.3 PRODUCTS OFFERED
15.1.4 TECHNOLOGY ANALYSIS
15.1.5 KEY DEVELOPMENTS
15.1.6 SWOT ANALYSIS
15.1.7 KEY STRATEGIES
15.2 WONDFO
15.2.1 COMPANY OVERVIEW
15.2.2 FINANCIAL OVERVIEW
15.2.3 PRODUCTS OFFERED
15.2.4 TECHNOLOGY
15.2.5 KEY DEVELOPMENTS
15.2.6 SWOT ANALYSIS
15.3 CHURCH & DWIGHT CO., INC. - FIRST RESPONSE
15.3.1 PRODUCTION OVERVIEW
15.3.2 FINANCIAL OVERVIEW
15.3.3 PRODUCTS OFFERED
15.3.4 TECHNOLOGY ANALYSIS
15.3.5 KEY DEVELOPMENTS
15.3.6 SWOT ANALYSIS
15.3.7 KEY STRATEGIES
15.4 HANGZHOU SINGCLEAN MEDICAL
15.4.1 COMPANY OVERVIEW
15.4.2 PRODUCTION OVERVIEW
15.4.3 FINANCIAL OVERVIEW
15.4.4 PRODUCT OFFERED
15.4.5 TECHNOLOGY ANALYSIS
15.4.6 KEY DEVELOPMENTS
15.4.7 KEY STRATEGIES
15.5 W.H.P.M., INC.
15.5.1 COMPANY OVERVIEW
15.5.2 PRODCUTION OVERVIEW
15.5.3 FINANCIAL
15.5.4 PRODUCTS OFFERED
15.5.5 TECHNOLOGY ANALYSIS
15.5.6 KEY STRATEGIES
15.6 SEKISUI DIAGNOSTICS
15.6.1 PRODUCTION OVERVIEW
15.6.2 FINANCIAL OVERVIEW
15.6.3 PRODUCTS OFFERED
15.6.4 TECHNOLOGY ANALYSIS
15.6.5 KEY DEVELOPMENTS
15.6.6 SWOT ANALYSIS
15.6.7 KEY STRATEGIES
15.7 INNOVITA BIOLOGICAL
15.7.1 COMPANY OVERVIEW
15.7.2 FINANCIAL OVERVIEW
15.7.3 PRODUCTS OFFERED
15.7.4 TECHNOLOGY ANALYSIS
15.7.5 KEY DEVELOPMENTS
15.7.6 KEY STRATEGIES
15.8 YANGZHOU VIOMED
15.8.1 COMPANY OVERVIEW
15.8.2 PRODUCTION OVERVIEW
15.8.3 FINANCIAL OVERVIEW
15.8.4 PRODUCTS
15.8.5 TECHNOLOGY ANALYSIS
15.8.6 KEY DEVELOPMENTS
15.9 COFOE MEDICAL TECHNOLOGY CO., LTD.
15.9.1 COMPANY
15.9.2 PRODUCTION OVERVIEW
15.9.3 FINANCIAL OVERVIEW
15.9.4 KEY DEVELOPMENTS
15.9.5 TECHNOLOGY ANALYSIS
15.9.6 SWOT ANALYSIS
15.9.7 KEY STRATEGIES
15.10 CHUNGDO PHARM CO.,
15.10.1 COMPANY OVERVIEW
15.10.2 PRODUCTION OVERVIEW
15.10.3 PROUDCTS OFFERED
15.10.4 TECHNOLOGY ANALYSIS
15.10.5 KEY DEVELOPMENTS
15.10.6 KEY STRATEGIES

16 DATA CITATIONS

17 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2035

18 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY AGE, 2019-2035

19 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SERUM, BY REGION, 2019-2035

20 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR LUTEINIZING HORMONE

21 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR GESTATIONAL DIABETES,

22 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2019-2035

23 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE,

24 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY,

25 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY TRANSMITTED

26 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2035

27 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS,

28 US: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE, 2019-2035

29 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

30 CANADA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE,

31 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2035

32 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS,

33 MEXICO: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

34 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

35 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE,

36 GERMANY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

37 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2035

38 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS,

39 FRANCE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

40 UK: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS,

41 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2035

42 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS,

43 ITALY: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

44 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2035

45 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS,

46 SPAIN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

47 REST OF EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR SEXUALLY

48 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION,

49 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION

50 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2035

51 CHINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

52 INDIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

53 JAPAN: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

54 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

55 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE,

56 AUSTRALIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

57 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE,

58 SOUTH KOREA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2035

59 SOUTH EAST ASIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION

60 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2035

61 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

62 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE,

63 MALAYSIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

64 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2035

65 SINGAPORE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE,

66 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

67 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE,

68 THAILAND: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

69 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2035

70 VIETNAM: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE,

71 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE, 2019-2035

72 PHILIPPINES: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITIONS,

73 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TECHNOLOGY, 2019-2035

74 INDONESIA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR ONLINE, BY TYPE,

75 REST OF ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE,

76 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT,

77 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY

78 MIDDLE EAST & AFRICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY

79 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2035

80 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION,

81 SOUTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY DISTRIBUTION

82 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY PRODUCT, 2019-2035

83 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY TEST TYPE 2019-2035

84 BRAZIL: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR OFFLINE, BY TYPE,

85 ARGENTINA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2035

86 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY SAMPLE TYPE, 2019-2035

87 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY APPLICATION, 2019-2035

88 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, FOR FERTILITY CONDITION,

89 CHILE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY END USER, 2019-2035

90 WONDFO: KEY DEVELOPMENTS

91 HANGZHOU SINGCLEAN MEDICAL PRODUCTS CO., LTD.: PRODUCTS OFFERED

92 SEKISUI DIAGNOSTICS: PRODUCTS OFFERED

93 YANGZHOU VIOMED CO., LTD.: PRODUCTS OFFERED

94 (USD BILLION)

95 GLOBAL POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE (%), BY END USER,

96 & 2035 (USD BILLION)

97 NORTH AMERICA: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2024

98 EUROPE: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET, BY COUNTRY, 2024 &

99 (USD BILLION)

100 ASIA-PACIFIC: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY,

101 & 2035 (USD BILLION)

102 REST OF THE WORLD: POINT-OF-CARE TESTING FOR WOMEN HEALTH MARKET SHARE, BY COUNTRY,

103 & 2035 (USD BILLION)

104 CHURCH & DWIGHT CO., INC.: SWOT ANALYSIS